8:
Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant.
Frogne T, Benjaminsen RV, Sonne-Hansen K, Sorensen BS, Nexo E, Laenkholm AV, Rasmussen LM, Riese DJ 2nd, de Cremoux P, Stenvang J, Lykkesfeldt AE.
Breast Cancer Res Treat. 2008 Apr 14. [Epub ahead of print]
PMID: 18409071 [PubMed - as supplied by publisher]
Related Articles
16:
Development of leiomyosarcoma of the uterus in MMTV-CR-1 transgenic mice.
Strizzi L, Bianco C, Hirota M, Watanabe K, Mancino M, Hamada S, Raafat A, Lawson S, Ebert AD, D'Antonio A, Losito S, Normanno N, Salomon DS.
J Pathol. 2007 Jan;211(1):36-44.
PMID: 17072826 [PubMed - indexed for MEDLINE]
Related Articles
17:
Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro.
Robinson MK, Hodge KM, Horak E, Sundberg AL, Russeva M, Shaller CC, von Mehren M, Shchaveleva I, Simmons HH, Marks JD, Adams GP.
Br J Cancer. 2008 Nov 4;99(9):1415-25. Epub 2008 Oct 7.
PMID: 18841159 [PubMed - indexed for MEDLINE]
Related Articles
18:
The effect of estradiol on in vivo tumorigenesis is modulated by the human epidermal growth factor receptor 2/phosphatidylinositol 3-kinase/Akt1 pathway.
Lehnes K, Winder AD, Alfonso C, Kasid N, Simoneaux M, Summe H, Morgan E, Iann MC, Duncan J, Eagan M, Tavaluc R, Evans CH Jr, Russell R, Wang A, Hu F, Stoica A.
Endocrinology. 2007 Mar;148(3):1171-80. Epub 2006 Nov 30.
PMID: 17138652 [PubMed - indexed for MEDLINE]
Related Articles
19:
Trastuzumab therapy vs tetracycline controlled ERBB2 downregulation: influence on tumour development in an ERBB2-dependent mouse tumour model.
Hermes M, Schormann W, Brulport M, Uhlemann K, Lupatsch F, Horn LC, Schumann A, Allgaier C, Weishaupt M, Engeland K, Müller GA, Mössner J, Bauer A, Schiffer IB, Gebhard S, Schmidt M, Lausch E, Prawitt D, Wilhelm C, Hengstler JG.
Br J Cancer. 2008 May 6;98(9):1525-32. Epub 2008 Apr 29.
PMID: 18454161 [PubMed - indexed for MEDLINE]
Related Articles